Abstract
Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
| Original language | English (US) |
|---|---|
| Journal | Annals of the Rheumatic Diseases |
| DOIs | |
| State | Accepted/In press - Nov 29 2016 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease : A case series. / Varkas, G.; Thevissen, K.; De Brabanter, G.; Van Praet, L.; Czul-gurdian, F.; Cypers, H.; De Kock, J.; Carron, P.; De Vos, M.; Hindryckx, P.; Arts, J.; Vanneuville, I.; Schoenaers, P.; Claerhout, B.; Abreu, Maria T; van den Bosch, F.; Elewaut, D.
In: Annals of the Rheumatic Diseases, 29.11.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease
T2 - A case series
AU - Varkas, G.
AU - Thevissen, K.
AU - De Brabanter, G.
AU - Van Praet, L.
AU - Czul-gurdian, F.
AU - Cypers, H.
AU - De Kock, J.
AU - Carron, P.
AU - De Vos, M.
AU - Hindryckx, P.
AU - Arts, J.
AU - Vanneuville, I.
AU - Schoenaers, P.
AU - Claerhout, B.
AU - Abreu, Maria T
AU - van den Bosch, F.
AU - Elewaut, D.
PY - 2016/11/29
Y1 - 2016/11/29
N2 - Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
AB - Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to a4ß7 integrin that modulates gut lymphocyte trafficking. Although an exclusively local effect of vedolizumab could be expected based on the restricted presence of the a4ß7-mucosal vascular addressin cell adhesion molecule 1 complex in the gut, past combined success with anti-tumour necrosis factor, and previous demonstration of a4ß7 integrin in the joint, led to the expectation of a therapeutic efficacy in spondyloarthritis. Nonetheless, the effect of vedolizumab on extraintestinal manifestations-and especially the joint-has not been reported so far. Case report A series of five patients with IBD who were treated with vedolizumab and promptly developed new onset or exacerbation of sacroiliitis or arthritis are reported. Conclusions Vedolizumab therapy does not seem to show any efficacy in and might even induce arthritis and/or sacroiliitis. However, larger cohort studies are needed to provide information on the prevalence, the evolution and underlying mechanism.
UR - http://www.scopus.com/inward/record.url?scp=85005963690&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85005963690&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2016-210233
DO - 10.1136/annrheumdis-2016-210233
M3 - Article
C2 - 27899374
AN - SCOPUS:85005963690
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
ER -